Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - rabeprazole sodium, quantity: 10 mg - tablet, enteric coated - excipient ingredients: diacetylated monoglycerides; hyprolose; magnesium stearate; purified water; light magnesium oxide; iron oxide red; hypromellose phthalate; carnauba wax; ethanol absolute; mannitol; titanium dioxide; purified talc; ethylcellulose - ? treatment and prevention of relapse of gastro-oesophageal reflux disease,? symptomatic treatment of gastro-oesophageal reflux disease,? treatment of duodenal ulcers,? treatment of gastric ulcers.,patients whose gastric and duodenal ulceration is not associated with ingestion of non-steroidal antiinflammatory,drugs (nsaids) usually require treatment with antimicrobial agents in addition to,antisecretory drugs whether on first presentation or on recurrence.,it is also indicated, in combination with clarithromycin and amoxycillin, for,? eradication of helicobacter pylori in patients with peptic ulcer disease or chronic gastritis,? healing of peptic ulcers in patients with helicobacter pylori associated ulcers.

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - rabeprazole sodium, quantity: 10 mg - tablet, enteric coated - excipient ingredients: hyprolose; magnesium stearate; diacetylated monoglycerides; purified talc; ethylcellulose; mannitol; titanium dioxide; light magnesium oxide; carnauba wax; purified water; ethanol absolute; iron oxide red; hypromellose phthalate - ? treatment and prevention of relapse of gastro-oesophageal reflux disease,? symptomatic treatment of gastro-oesophageal reflux disease,? treatment of duodenal ulcers,? treatment of gastric ulcers.,patients whose gastric and duodenal ulceration is not associated with ingestion of non-steroidal antiinflammatory,drugs (nsaids) usually require treatment with antimicrobial agents in addition to,antisecretory drugs whether on first presentation or on recurrence.,it is also indicated, in combination with clarithromycin and amoxycillin, for,? eradication of helicobacter pylori in patients with peptic ulcer disease or chronic gastritis,? healing of peptic ulcers in patients with helicobacter pylori associated ulcers.

Australia - English - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - rabeprazole sodium, quantity: 10 mg - tablet, enteric coated - excipient ingredients: mannitol; titanium dioxide; diacetylated monoglycerides; crospovidone; hypromellose phthalate; light magnesium oxide; ethylcellulose; hyprolose; magnesium stearate; purified talc; heavy magnesium oxide - indicated for: ,? treatment and prevention of relapse of gastro-oesophageal reflux disease ,? symptomatic treatment of gastro-oesophageal reflux disease ,? treatment of duodenal ulcers ,? treatment of gastric ulcers. ,patients whose gastric and duodenal ulceration is not associated with ingestion of non-steroidal anti-inflammatory drugs (nsaids) usually require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence. ,also indicated, in combination with clarithromycin and amoxycillin, for: ,? eradication of helicobacter pylori in patients with peptic ulcer disease or chronic gastritis ,? healing of peptic ulcers in patients with helicobacter pylori associated ulcers.

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - rabeprazole sodium, quantity: 10 mg - tablet, enteric coated - excipient ingredients: hyprolose; diacetylated monoglycerides; crospovidone; magnesium stearate; purified talc; hypromellose phthalate; ethylcellulose; light magnesium oxide; mannitol; titanium dioxide; heavy magnesium oxide - indicated for: ,? treatment and prevention of relapse of gastro-oesophageal reflux disease ,? symptomatic treatment of gastro-oesophageal reflux disease ,? treatment of duodenal ulcers ,? treatment of gastric ulcers. ,patients whose gastric and duodenal ulceration is not associated with ingestion of non-steroidal anti-inflammatory drugs (nsaids) usually require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence. ,also indicated, in combination with clarithromycin and amoxycillin, for: ,? eradication of helicobacter pylori in patients with peptic ulcer disease or chronic gastritis ,? healing of peptic ulcers in patients with helicobacter pylori associated ulcers.

Australia - English - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - rabeprazole sodium, quantity: 20 mg - tablet, enteric coated - excipient ingredients: ethylcellulose; titanium dioxide; mannitol; crospovidone; magnesium stearate; iron oxide yellow; diacetylated monoglycerides; heavy magnesium oxide; light magnesium oxide; purified talc; hyprolose; hypromellose phthalate - indicated for: ,? treatment and prevention of relapse of gastro-oesophageal reflux disease ,? symptomatic treatment of gastro-oesophageal reflux disease ,? treatment of duodenal ulcers ,? treatment of gastric ulcers. ,patients whose gastric and duodenal ulceration is not associated with ingestion of non-steroidal anti-inflammatory drugs (nsaids) usually require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence. ,also indicated, in combination with clarithromycin and amoxycillin, for: ,? eradication of helicobacter pylori in patients with peptic ulcer disease or chronic gastritis ,? healing of peptic ulcers in patients with helicobacter pylori associated ulcers.

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - rabeprazole sodium, quantity: 20 mg - tablet, enteric coated - excipient ingredients: diacetylated monoglycerides; heavy magnesium oxide; light magnesium oxide; hyprolose; ethylcellulose; magnesium stearate; purified talc; crospovidone; mannitol; titanium dioxide; hypromellose phthalate; iron oxide yellow - indicated for: ,? treatment and prevention of relapse of gastro-oesophageal reflux disease ,? symptomatic treatment of gastro-oesophageal reflux disease ,? treatment of duodenal ulcers ,? treatment of gastric ulcers. ,patients whose gastric and duodenal ulceration is not associated with ingestion of non-steroidal anti-inflammatory drugs (nsaids) usually require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence. ,also indicated, in combination with clarithromycin and amoxycillin, for: ,? eradication of helicobacter pylori in patients with peptic ulcer disease or chronic gastritis ,? healing of peptic ulcers in patients with helicobacter pylori associated ulcers.

Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - rabeprazole sodium, quantity: 20 mg - tablet, enteric coated - excipient ingredients: mannitol; magnesium stearate; carnauba wax; titanium dioxide; purified talc; hypromellose phthalate; diacetylated monoglycerides; ethylcellulose; magnesium oxide; hyprolose; iron oxide yellow; butan-1-ol; shellac; iron oxide red; ethanol absolute; glyceryl monooleate - pariet is indicated for treatment and prevention of relapse of gastro-oesophageal reflux disease; symptomatic treatment gastro-oesophageal reflux disease; treatment of duodenal ulcers; treatment of gastric ulcers. patients whose gastric and duodenal ulceration is not associated with ingestion of non-steroidal anti-inflammatory drugs (nsaids) usually require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence. pariet is also indicated, in combination with clarithromycin and amoxycillin, for eradication of helicobacter pylori in patients with peptic ulcer disease or chronic gastritis; and healing of peptic ulcers in patients with helicobacter pylori associated ulcers.

Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - rabeprazole sodium, quantity: 10 mg - tablet, enteric coated - excipient ingredients: purified talc; magnesium stearate; iron oxide red; magnesium oxide; titanium dioxide; mannitol; carnauba wax; hypromellose phthalate; hyprolose; ethylcellulose; diacetylated monoglycerides; butan-1-ol; shellac; ethanol absolute; iron oxide black - pariet is indicated for treatment and prevention of relapse of gastro-oesophageal reflux disease; symptomatic treatment gastro-oesophageal reflux disease; treatment of duodenal ulcers; treatment of gastric ulcers. patients whose gastric and duodenal ulceration is not associated with ingestion of non-steroidal anti-inflammatory drugs (nsaids) usually require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence. pariet is also indicated, in combination with clarithromycin and amoxycillin, for eradication of helicobacter pylori in patients with peptic ulcer disease or chronic gastritis; and healing of peptic ulcers in patients with helicobacter pylori associated ulcers.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: sucrose; mannitol; glycerol; iron oxide yellow; hypromellose; microcrystalline cellulose; magnesium stearate; croscarmellose sodium; polysorbate 80; iron oxide red; hydrogenated vegetable oil; titanium dioxide - comtan is indicated in the management of parkinson's disease as an adjunct to levodopa/dopa decarboxylase inhibitor therapy in patients who are experiencing motor fluctuations (see clinical trials).

Australia - English - Department of Health (Therapeutic Goods Administration)

orion pharma (aus) pty limited - selegiline hydrochloride, quantity: 5 mg - tablet, uncoated - excipient ingredients: magnesium stearate; povidone; maize starch; microcrystalline cellulose; mannitol - as an adjunct in the management of late stage parkinson's disease in patients being treated with levodopa and/or a peripheral decarboxylase inhibitor, who exhibit deterioration in the quality of their response to the therapy. indications as approved 22 january 1999 - eldepryl is indicated for the treatment of patients with parkinson's disease. it can be used as monotherapy in the early phases of the disease and as adjunctive therapy with levodopa (with/without a peripheral decarboxylase inhibitor) as an adjunct in the management of late stage parkinson's disease in patients being treated with levodopa and/or a peripheral decarboxylase inhibitor, who exhibit deterioration in the quality of their response to the therapy. indications as approved 22 january 1999 - eldepryl is indicated for the treatment of patients with parkinson's disease. it can be used as monotherapy in the early phases of the disease and as adjunctive therapy with levodopa (with/without a peripheral decarboxylase inhibitor)